Literature DB >> 18266893

Comparison of properties of tests for assessing tumor clonality.

Irina Ostrovnaya1, Venkatraman E Seshan, Colin B Begg.   

Abstract

SUMMARY: In a recent article Begg et al. (2007, Biometrics 63, 522-530) proposed a statistical test to determine whether or not a diagnosed second primary tumor is biologically independent of the original primary tumor, by comparing patterns of allelic losses at candidate genetic loci. The proposed concordant mutations test is a conditional test, an adaptation of Fisher's exact test, that requires no knowledge of the marginal mutation probabilities. The test was shown to have generally good properties, but is susceptible to anticonservative bias if there is wide variation in mutation probabilities between loci, or if the individual mutation probabilities of the parental alleles for individual patients differ substantially from each other. In this article, a likelihood ratio test is derived in an effort to address these validity issues. This test requires prespecification of the marginal mutation probabilities at each locus, parameters for which some information will typically be available in the literature. In simulations this test is shown to be valid, but to be considerably less efficient than the concordant mutations test for sample sizes (numbers of informative loci) typical of this problem. Much of the efficiency deficit can be recovered, however, by restricting the allelic imbalance parameter estimate to a prespecified range, assuming that this parameter is in the prespecified range.

Entities:  

Mesh:

Year:  2008        PMID: 18266893      PMCID: PMC2761024          DOI: 10.1111/j.1541-0420.2008.00988.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  7 in total

1.  Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis.

Authors:  J Huang; C Behrens; I Wistuba; A F Gazdar; J Jagirdar
Journal:  Ann Diagn Pathol       Date:  2001-12       Impact factor: 2.090

2.  Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary?

Authors:  Tom W Geurts; Petra M Nederlof; Michiel W M van den Brekel; Laura J van't Veer; Daphne de Jong; August A M Hart; Nico van Zandwijk; Houke Klomp; Alfons J M Balm; Marie-Louise F van Velthuysen
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

3.  Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas.

Authors:  Evgeny N Imyanitov; Evgeny N Suspitsin; Maxim Yu Grigoriev; Alexandr V Togo; Ekatherina Sh Kuligina; Evgeniya V Belogubova; Kazymir M Pozharisski; Elena A Turkevich; Carmen Rodriquez; Cees J Cornelisse; Kaido P Hanson; Charles Theillet
Journal:  Int J Cancer       Date:  2002-08-10       Impact factor: 7.396

Review 4.  Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies.

Authors:  Christian Hafner; Ruth Knuechel; Robert Stoehr; Arndt Hartmann
Journal:  Int J Cancer       Date:  2002-09-01       Impact factor: 7.396

5.  Statistical tests for clonality.

Authors:  Colin B Begg; Kevin H Eng; Amanda J Hummer
Journal:  Biometrics       Date:  2007-06       Impact factor: 2.571

Review 6.  The molecular biology of mucosal field cancerization of the head and neck.

Authors:  Patrick K Ha; Joseph A Califano
Journal:  Crit Rev Oral Biol Med       Date:  2003

7.  Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.

Authors:  P P Leong; B Rezai; W M Koch; A Reed; D Eisele; D J Lee; D Sidransky; J Jen; W H Westra
Journal:  J Natl Cancer Inst       Date:  1998-07-01       Impact factor: 13.506

  7 in total
  8 in total

1.  Testing clonal relatedness of tumors using array comparative genomic hybridization: a statistical challenge.

Authors:  Irina Ostrovnaya; Colin B Begg
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data.

Authors:  Irina Ostrovnaya; Adam B Olshen; Venkatraman E Seshan; Irene Orlow; Donna G Albertson; Colin B Begg
Journal:  Stat Med       Date:  2010-07-10       Impact factor: 2.373

3.  Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles.

Authors:  Irina Ostrovnaya; Venkatraman E Seshan; Adam B Olshen; Colin B Begg
Journal:  Bioinformatics       Date:  2011-05-05       Impact factor: 6.937

4.  USING SOMATIC MUTATION DATA TO TEST TUMORS FOR CLONAL RELATEDNESS.

Authors:  Irina Ostrovnaya; Venkatraman E Seshan; Colin B Begg
Journal:  Ann Appl Stat       Date:  2015-11-02       Impact factor: 2.083

Review 5.  Testing clonality of three and more tumors using their loss of heterozygosity profiles.

Authors:  Irina Ostrovnaya
Journal:  Stat Appl Genet Mol Biol       Date:  2012-07-13

6.  DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.

Authors:  Richard M Bambury; Ami S Bhatt; Markus Riester; Chandra Sekhar Pedamallu; Fujiko Duke; Joaquim Bellmunt; Edward C Stack; Lillian Werner; Rachel Park; Gopa Iyer; Massimo Loda; Philip W Kantoff; Franziska Michor; Matthew Meyerson; Jonathan E Rosenberg
Journal:  BMC Cancer       Date:  2015-04-09       Impact factor: 4.430

7.  Clonal relatedness in tumour pairs of breast cancer patients.

Authors:  Jana Biermann; Toshima Z Parris; Szilárd Nemes; Anna Danielsson; Hanna Engqvist; Elisabeth Werner Rönnerman; Eva Forssell-Aronsson; Anikó Kovács; Per Karlsson; Khalil Helou
Journal:  Breast Cancer Res       Date:  2018-08-09       Impact factor: 6.466

8.  Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors.

Authors:  Lei Bao; Karen Messer; Richard Schwab; Olivier Harismendy; Minya Pu; Brian Crain; Shawn Yost; Kelly A Frazer; Brinda Rana; Farnaz Hasteh; Anne Wallace; Barbara A Parker
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.